Clinical Trials Logo

Filter by:
NCT ID: NCT03209518 Completed - Clinical trials for Premenopausal Breast Cancer

Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"

Start date: March 18, 2016
Phase:
Study type: Observational

The purpose of this survey is to evaluate the safety in patients with premenopausal breast cancer receiving Leuprorelin in the routine clinical setting.

NCT ID: NCT03209492 Completed - Prostate Cancer Clinical Trials

Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"

Start date: April 1, 2016
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety in patients with prostate cancer receiving the drug in the routine clinical setting.

NCT ID: NCT03209479 Completed - Multiple Sclerosis Clinical Trials

Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"

Start date: November 24, 2015
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety and efficacy of Copaxone subcutaneous injection syringe (hereinafter referred to as Copaxone) in patients with multiple sclerosis in the routine clinical setting.

NCT ID: NCT03205163 Completed - Hemophilia A Clinical Trials

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

Start date: August 28, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose was to assess the safety and tolerability of a single intravenous (IV) administration of BIVV001 in adult previously treated patients (PTPs) with severe hemophilia A.

NCT ID: NCT03203876 Completed - Advanced Cancer Clinical Trials

A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

Start date: July 14, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether lirilumab in combination with nivolumab or in combination with nivolumab and ipilimumab is safe in the treatment of advanced and/or metastatic solid tumors

NCT ID: NCT03201900 Completed - Clinical trials for Partial Onset Seizures

Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)

Start date: June 28, 2017
Phase: Phase 3
Study type: Interventional

This study is conducted to evaluate the seizure-free rate of the 26-week Maintenance Period in untreated participants with partial onset seizures (POS).

NCT ID: NCT03198715 Completed - Clinical trials for Acute Ischemic Stroke

Safety of DS-1040b in Acute Ischemic Stroke Patients Treated With Thrombectomy

Start date: July 30, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to find out if DS-1040b is safe and tolerable in acute ischemic stroke patients with thrombectomy. Four groups will receive different doses of DS-1040b by intravenous infusion for 6 hours. Groups with the lowest dose will start. When it is determined that each dose is safe and tolerable, the next higher dose will be given to the next group.

NCT ID: NCT03197935 Completed - Clinical trials for Triple-negative Breast Cancer

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

IMpassion031
Start date: July 24, 2017
Phase: Phase 3
Study type: Interventional

This is a global Phase III, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) and nab-paclitaxel followed by doxorubicin and cyclophosphamide (nab-pac-AC), or placebo and nab-pac-AC in participants eligible for surgery with initial clinically assessed triple-negative breast cancer (TNBC).

NCT ID: NCT03197766 Completed - Achondroplasia Clinical Trials

A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

Start date: December 12, 2016
Phase: Phase 3
Study type: Interventional

The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia.

NCT ID: NCT03196297 Completed - Haemophilia A Clinical Trials

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

explorerâ„¢5
Start date: August 16, 2017
Phase: Phase 2
Study type: Interventional

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in patients with severe haemophilia A without inhibitors.